Clinical Study on the Treatment of Chronic Heart Failure with Different Doses of Sacubitril Valsartan Sodium Combined with Qili Qiangxin Capsules
Objective:To analyze the effects of different doses of Sacubitril Valsartan Sodium combined with Qili Qiangxin Capsules on patients with chronic heart failure(CHF).Method:A total of 60 CHF patients admitted to Xinyu Yuanhe Hospital from September 2021 to August 2023 were selected and randomly divided into two groups,with 30 patients in each group.The control group was treated with low-dose Sacubitril Valsartan Sodium(25 mg/time,2 times/day)combined with Qili Qiangxin Capsules,while the observation group was treated with high-dose Sacubitril Valsartan Sodium(50 mg/time,2 times/day)combined with Qili Qiangxin Capsules,lasting for 1 month.The clinical efficacy,cardiac function indexes,serological indexes,exercise endurance,quality of life and incidence of adverse reactions were compared between two groups.Result:The total effective rate of the observation group was 93.33%,which was higher than 73.33%of the control group,the difference was statistically significant(P<0.05).After treatment,the left ventricular ejection fraction(LVEF)of the observation group was higher than that of the control group,the left ventricular end diastolic diameter(LVEDD),the left ventricular end systolic diameter(LVESD),the N-terminal B-type natriuretic peptide precursor(NT-proBNP),the cardiac troponin I(cTnI)and Minnesota living with heart failure questionnaire(MLHFQ)score were lower than those of the control group,the distance of 6 min walking test(6MWT)was longer than that of control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:High-dose of Sacubitril Valsartan Sodium combined with Qili Qiangxin Capsules can effectively improve cardiac function,protect cardiomyocytes,enhance exercise endurance and improve quality of life in patients with CHF,without serious adverse reactions.
万方数据
维普
